Symbols

Symbols

SNGX

SNGX

Soligenix reports Q3 results, anticipates year-end milestones.

Tuesday Oct 14, 2025

Soligenix updates US Medical Advisory Board for HyBryte clinical development.

Soligenix Updates Medical Advisory Board for Cutaneous T-Cell Lymphoma Treatment

Tuesday Oct 07, 2025

Soligenix Reports Positive Data from HyBryte Phase 3 Study in CTCL.

Friday Oct 03, 2025

Soligenix Inc Insider Buying: Christopher Schaber Purchases 15,132 Shares

Soligenix CEO Christopher Schaber Buys 15,132 Shares at $1.32 Per Share

Tuesday Sep 30, 2025

Soligenix expands European Medical Advisory Board for HyBryte clinical study.

Monday Sep 29, 2025

Soligenix Enters Securities Purchase Agreement with Investors on September 25: SEC Filing

Soligenix Announces $7.5M Public Offering with Institutional Investors.

Saturday Sep 27, 2025

Soligenix (SNGX) Initiates Public Offering to Raise $7.5 Million, Aims to Support R&D and Commercialization Efforts

Friday Sep 26, 2025

Soligenix Raises $7.5mln in Public Offering, Stock Up 27% in Pre-market

Soligenix Announces $7.5 Million Public Offering to Fund Research, Development, and Commercialization Activities.

Soligenix prices public offering of common stock and warrants for $7.4M.

Tuesday Sep 23, 2025

Soligenix Appoints Tomas J. Philipson as Strategic Advisor

Soligenix Appoints Former White House Economic Adviser Tomas J. Philipson as Strategic Advisor

Friday Sep 19, 2025

Soligenix shares fall 7.06% after-hours following a corporate presentation on rare disease treatment.

Friday Sep 05, 2025

Soligenix shares fall 5.59% premarket after announcing long-term stability of ebolavirus vaccines.

Thursday Sep 04, 2025

Soligenix's 15min chart sees MACD Death Cross, KDJ Death Cross triggered.

Soligenix Announces Extended Stability of Ebolavirus Vaccines Using ThermoVax Platform

Wednesday Sep 03, 2025

Soligenix's 15min chart sees KDJ Golden Cross, bullish Marubozu signal.